In multiple myeloma, NEK2 inhibits its own and Beclin1 degradation by binding to ubiquitin-specific protease 7(USP7), thereby activating classical NF-κB signaling and autophagy pathways, promoting disease progression and resistance to bortezomib [41, 43]. Here, BECN1 is linked to plasma cell myeloma.